Cargando…

Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma

Wiskott–Aldrich Syndrome (WAS) is a severe X-linked Primary Immunodeficiency that affects 1–10 out of 1 million male individuals. WAS is caused by mutations in the WAS Protein (WASP) expressing gene that leads to the absent or reduced expression of the protein. WASP is a cytoplasmic protein that reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Catucci, Marco, Castiello, Maria Carmina, Pala, Francesca, Bosticardo, Marita, Villa, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399097/
https://www.ncbi.nlm.nih.gov/pubmed/22826711
http://dx.doi.org/10.3389/fimmu.2012.00209
_version_ 1782238363366981632
author Catucci, Marco
Castiello, Maria Carmina
Pala, Francesca
Bosticardo, Marita
Villa, Anna
author_facet Catucci, Marco
Castiello, Maria Carmina
Pala, Francesca
Bosticardo, Marita
Villa, Anna
author_sort Catucci, Marco
collection PubMed
description Wiskott–Aldrich Syndrome (WAS) is a severe X-linked Primary Immunodeficiency that affects 1–10 out of 1 million male individuals. WAS is caused by mutations in the WAS Protein (WASP) expressing gene that leads to the absent or reduced expression of the protein. WASP is a cytoplasmic protein that regulates the formation of actin filaments in hematopoietic cells. WASP deficiency causes many immune cell defects both in humans and in the WAS murine model, the Was(−/−) mouse. Both cellular and humoral immune defects in WAS patients contribute to the onset of severe clinical manifestations, in particular microthrombocytopenia, eczema, recurrent infections, and a high susceptibility to develop autoimmunity and malignancies. Autoimmune diseases affect from 22 to 72% of WAS patients and the most common manifestation is autoimmune hemolytic anemia, followed by vasculitis, arthritis, neutropenia, inflammatory bowel disease, and IgA nephropathy. Many groups have widely explored immune cell functionality in WAS partially explaining how cellular defects may lead to pathology. However, the mechanisms underlying the occurrence of autoimmune manifestations have not been clearly described yet. In the present review, we report the most recent progresses in the study of immune cell function in WAS that have started to unveil the mechanisms contributing to autoimmune complications in WAS patients.
format Online
Article
Text
id pubmed-3399097
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33990972012-07-23 Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma Catucci, Marco Castiello, Maria Carmina Pala, Francesca Bosticardo, Marita Villa, Anna Front Immunol Immunology Wiskott–Aldrich Syndrome (WAS) is a severe X-linked Primary Immunodeficiency that affects 1–10 out of 1 million male individuals. WAS is caused by mutations in the WAS Protein (WASP) expressing gene that leads to the absent or reduced expression of the protein. WASP is a cytoplasmic protein that regulates the formation of actin filaments in hematopoietic cells. WASP deficiency causes many immune cell defects both in humans and in the WAS murine model, the Was(−/−) mouse. Both cellular and humoral immune defects in WAS patients contribute to the onset of severe clinical manifestations, in particular microthrombocytopenia, eczema, recurrent infections, and a high susceptibility to develop autoimmunity and malignancies. Autoimmune diseases affect from 22 to 72% of WAS patients and the most common manifestation is autoimmune hemolytic anemia, followed by vasculitis, arthritis, neutropenia, inflammatory bowel disease, and IgA nephropathy. Many groups have widely explored immune cell functionality in WAS partially explaining how cellular defects may lead to pathology. However, the mechanisms underlying the occurrence of autoimmune manifestations have not been clearly described yet. In the present review, we report the most recent progresses in the study of immune cell function in WAS that have started to unveil the mechanisms contributing to autoimmune complications in WAS patients. Frontiers Research Foundation 2012-07-18 /pmc/articles/PMC3399097/ /pubmed/22826711 http://dx.doi.org/10.3389/fimmu.2012.00209 Text en Copyright © 2012 Catucci, Castiello, Pala, Bosticardo and Villa. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Immunology
Catucci, Marco
Castiello, Maria Carmina
Pala, Francesca
Bosticardo, Marita
Villa, Anna
Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title_full Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title_fullStr Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title_full_unstemmed Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title_short Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma
title_sort autoimmunity in wiskott–aldrich syndrome: an unsolved enigma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399097/
https://www.ncbi.nlm.nih.gov/pubmed/22826711
http://dx.doi.org/10.3389/fimmu.2012.00209
work_keys_str_mv AT catuccimarco autoimmunityinwiskottaldrichsyndromeanunsolvedenigma
AT castiellomariacarmina autoimmunityinwiskottaldrichsyndromeanunsolvedenigma
AT palafrancesca autoimmunityinwiskottaldrichsyndromeanunsolvedenigma
AT bosticardomarita autoimmunityinwiskottaldrichsyndromeanunsolvedenigma
AT villaanna autoimmunityinwiskottaldrichsyndromeanunsolvedenigma